CONGRESS ASSET MANAGEMENT CO

Position in LGND — Ligand Pharmaceuticals Inc

CIK 897378 BOSTON, MA

Position in LGND

as of Jun 30, 2026 · filed Jul 7, 2026 Compact

Position Value

$208,591,267

+$107,840,490 QoQ

Shares Held

659,911

+30.8% QoQ

Ownership

3.29%

of shares outstanding

% of Portfolio

1.30%

of 13F equity value

Holder Rank

of 26 holders

Holding Since

Mar 2020

12 quarters on record

Voting authority Sole 94.41409523405429.ToString("F0")% Shared 3.0652618307620267.ToString("F0")% None 2.520642935183684.ToString("F0")%

Healthcare · as of Jun 30, 2026

CONGRESS ASSET MANAGEMENT CO holds $715,705,658 across 14 Biotechnology names. LGND ranks #1 (29.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	LGND	Ligand Pharmaceuticals Inc This page	659,911	$208,591,267
2	TGTX	Tg Therapeutics, Inc.	2,600,123	$142,850,757
3	VCEL	Vericel Corp	2,916,295	$129,745,964
4	HALO	Halozyme Therapeutics, Inc.	1,229,106	$96,202,126
5	ALNY	Alnylam Pharmaceuticals, Inc.	265,701	$79,983,972
6	KRYS	Krystal Biotech, Inc.	40,134	$14,916,603
7	TNGX	Tango Therapeutics, Inc.	380,746	$11,902,119
8	RLAY	Relay Therapeutics, Inc.	626,141	$11,715,098

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$208,591,267	659,911	+30.8%	Shares	Sole	2026-07-07
2026-03-31	$100,750,777	504,637	+5.1%	Shares	Sole	2026-04-14
2025-12-31	$90,765,511	480,063	-28.1%	Shares	Sole	2026-01-09
2025-09-30	$118,207,470	667,311	+3.0%	Shares	Sole	2025-10-10
2025-06-30	$73,657,932	647,941	+0.8%	Shares	Sole	2025-07-16
2025-03-31	$67,574,739	642,712	+3.4%	Shares	Sole	2025-04-11
2024-12-31	$66,591,796	621,482	+2.9%	Shares	Sole	2025-01-30
2024-09-30	$60,458,163	604,038	+3.0%	Shares	Sole	2024-10-28
2024-06-30	$49,428,938	586,624	+1712.0%	Shares	Sole	2024-08-02
2020-09-30	$1,925,130	32,375	+4.6%	Shares	Sole	2020-11-03
2020-06-30	$2,159,339	30,947	+2.2%	Shares	Sole	2020-07-23
2020-03-31	$1,374,193	30,292	—	Shares	Sole	2020-04-21
No filing history on record for this holder in this stock.